Second Amendment to Study Funding Agreement between Hollis-Eden Pharmaceuticals, Inc. and Cystic Fibrosis Foundation Therapeutics, Inc.
This letter agreement, dated June 12, 2008, amends a previous Study Funding Agreement between Hollis-Eden Pharmaceuticals, Inc. and Cystic Fibrosis Foundation Therapeutics, Inc. The amendment specifically changes the language in Section 8.1(c) of the original agreement, with all other terms remaining unchanged. Both parties have agreed to this modification, as indicated by their signatures. The agreement ensures that the rest of the original contract remains in effect.
EXHIBIT 10.61
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
June 12, 2008
Dr. Diana Wetmore
Cystic Fibrosis Foundation Therapeutics, Inc.
6931 Arlington Road
Bethesda, MD 20814
Dear Dr. Wetmore:
The purpose of this letter (“Letter”) is to further amend the Study Funding Agreement, between the undersigned parties, dated June 17, 2003, as amended (the “Agreement”). By signing below, the undersigned parties agree to the following:
In Section 8.1(c) of the Agreement, [ * ] shall be replaced with [ * ].
All other terms and provisions of the Agreement shall remain unchanged and are in full force and effect.
| HOLLIS-EDEN PHARMACEUTICALS, INC. | ||||||
| By: | /s/ Robert W. Weber | Date: 6/12/08 | ||||
| Robert W. Weber | ||||||
| Interim Chief Financial Officer, | ||||||
| Chief Accounting Officer and | ||||||
| Vice President, Operations | ||||||
Agreed to and Acknowledged by:
| CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. | ||||||
| By: | /s/ Robert J. Beall | Date: 6/25/08 | ||||
| Robert J. Beall, Ph.D. | ||||||
| President and CEO | ||||||
